Advertisement

Topics

Biotie announces start of tozadenant Phase 3 Study in Parkinson's disease

04:01 EDT 21 Jul 2015 | GlobalNewsWire (2014)

This article has expired, however you can still download the PDF.
Preview:
BIOTIE THERAPIES CORP.     STOCK EXCHANGE RELEASE                 21July 2015 at 09.00 a.m. Biotie announces start of tozadenant Phase 3 Study in Parkinson's disease Biotie (Nasdaq Helsinki BTH1V; NASDAQ: BITI) announces the ...

Other Sources for this Article

NEXT ARTICLE

More From BioPortfolio on "Biotie announces start of tozadenant Phase 3 Study in Parkinson's disease"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Parkinson's Disease
Parkinson's is a progressive neurological condition, affecting one person in every 500, 95% of which are over 40. It is caused by degeneration of more than 70% of the substantia nigra, which depletes the dopamine (the neurotransmitter involved in pro...

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...